8-K
filed December 11, 2023, 6:59 PM ET
ticker GALT
CIK 0001133416
other material
confidence high
sentiment neutral
materiality 0.15
Galectin Therapeutics announces 2023 annual meeting results; all director nominees elected
GALECTIN THERAPEUTICS INC
- All 11 director nominees elected; highest vote total for Kary Eldred at 25,603,577 for.
- Ratification of Cherry Bekaert LLP as auditor approved: 44,481,830 for, 252,254 against.
- Amendment to 2019 Omnibus Equity Incentive Plan to add 3,000,000 shares approved: 23,901,293 for, 1,923,578 against, 18,910,166 broker non-votes.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
GALECTIN THERAPEUTICS INC shareholders approved Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023 at the 2023-12-07 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-12-07
Exact text from the filing
Ratification of the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2023 Votes For Votes Against Votes Abstain 44,481,830 252,254 187,704
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
GALECTIN THERAPEUTICS INC shareholders approved Election of Directors at the 2023-12-07 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-12-07
Exact text from the filing
Election of Directors Name Votes For Votes Withheld Broker Non-Votes Gilbert F. Amelio, Ph.D. 24,856,340 1,155,282 18,910,166
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
GALECTIN THERAPEUTICS INC shareholders approved Approved an amendment to our 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance under the plan at the 2023-12-07 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-12-07
Exact text from the filing
Approved an amendment to our 2019 Omnibus Equity Incentive Plan to reserve an additional 3,000,000 shares for issuance under the plan. Votes For Votes Against Votes Abstain Broker Non-Votes 23,901,293 1,923,578 186,751 18,910,166
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.